Revolution Medicines (RVMD) Net Margin (2019 - 2023)

Revolution Medicines' Net Margin history runs 5 years deep, the most recent figure standing at 21770.49% for Q4 2023.

• In Q4 2023, Net Margin fell 2140175.0% year-over-year to 21770.49%; the TTM figure through Sep 2024 stood at 76423.32% (down 7515705.0% YoY), while the FY2023 annual figure was 3768.28%, down 306533.0% from the prior year.
• Net Margin for Q4 2023 stood at 21770.49%, down from 2570.55% in the prior quarter.
• The five-year high for Net Margin was 97.27% in Q1 2019, with the low at 21770.49% in Q4 2023.
• The 5-year median for Net Margin is 390.86% (2020), against an average of 1952.74%.
• The sharpest annual moves came in 2022 and 2023: Net Margin soared 262334 bps in 2022, then plunged 2140175 bps in 2023.
• Revolution Medicines' Net Margin stood at 155.91% in 2019, then sank by 151 bps to 390.86% in 2020, then tumbled by 42 bps to 556.83% in 2021, then surged by 34 bps to 368.73% in 2022, then plunged by 5804 bps to 21770.49% in 2023.
• Business Quant data shows RVMD's Net Margin at 21770.49% in Q4 2023, 2570.55% in Q2 2023, and 970.89% in Q1 2023.